Sulforaphane activates CD8 + T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’

Jinyan Liu,Huanan Chen,Caijuan Guo,Jieyao Li,Miaomiao Li,Ming Zhao,Ziyi Fu,Zhen Zhang,Feng Li,Xuan Zhao,Li Yang,Liping Wang,Quanjun Lv,Yi Zhang
DOI: https://doi.org/10.1136/jitc-2023-007983
IF: 12.469
2024-01-01
Journal for ImmunoTherapy of Cancer
Abstract:Background Extensive attention has been given to the role of myeloid-derived suppressor cells (MDSCs) in driving tumor progression and treatment failure. Preclinical studies have identified multiple agents that eliminate MDSCs. However, none have been authorized in the cliniccal ues due to the safety reasons. In the present study, we investigated the efficacy and mechanism of sulforaphane (SFN) to eliminate MDSCs in the tumor microenvironment (TME). Methods We monitored SFN effect on tumor growth and the percents or apoptosis of immune cell subsets in mice models bearing LLC or B16 cells. Flow cytometry, quantitative reverse transcription-PCR, immunohistochemistry, ELISA, immunofluorescence, imaging flow cytometry and western blot were performed to validate the role of SFN on MDSCs function in vivo and in vitro. RNA sequencing was then used to interrogate the mechanisms of how SFN regulated MDSCs function. Tumor xenograft models were established to evaluate the involvement of IL-12RB2/MMP3/FasL induced MDSCs apoptosis in vivo. We verified the effect of SFN on MDSCs and CD8 + T cells in the blood samples from a phase I clinical trial (KY-2021–0350). Results In this study, we elucidated that SFN liberated CD8 + T-cell antitumor ability by reducing MDSCs abundance, leading to repressed tumor growth. SFN treatment suppressed MDSCs accumulation in the peripheral blood and tumor sites of mice, but had no effect on the bone marrow. Mechanistically, SFN activates IL-12RB2, which stimulates the MMP3/FasL signaling cascade to trigger caspase 3 cleavage and induce apoptosis in MDSCs. Clinically, SFN treatment eliminates peripheral MDSCs and increases the percentage and activation of CD8 + T cells. Conclusions Collectively, we uncovered the role of SFN in eliminating MDSCs to emancipate CD8 + T cells through IL-12RB2/MMP3/FasL induced apoptosis, thus providing a strategy for targeting MDSCs to control tumors and improve clinical efficacy.
oncology,immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: **How to enhance the anti - tumor immune response of CD8+ T cells by eliminating myeloid - derived suppressor cells (MDSCs), thereby inhibiting tumor growth**. Specifically, the researchers focused on the role of the natural compound **sulforaphane (SFN)** in the tumor microenvironment (TME). They found that SFN can induce apoptosis of MDSCs by activating the IL - 12RB2/MMP3/FasL signaling pathway, thereby reducing the number of MDSCs, liberating the suppressed CD8+ T - cell function, and ultimately achieving the effect of inhibiting tumor growth. ### Main research questions: 1. **Can SFN effectively inhibit the function of MDSCs and promote the anti - tumor activity of CD8+ T cells?** - The researchers verified the influence of SFN on MDSCs through a variety of experiments, including in vitro and in vivo experiments. 2. **By what mechanism does SFN induce MDSCs apoptosis?** - Research shows that SFN activates the IL - 12RB2 receptor, further stimulates the MMP3/FasL signaling pathway, leading to caspase 3 cleavage, and finally triggers MDSCs apoptosis. 3. **What are the effects of SFN in pre - clinical and clinical trials?** - The researchers observed in a mouse model that SFN significantly inhibited tumor growth, and a similar effect was also found in a phase I clinical trial, that is, the number of MDSCs in peripheral blood was reduced, and the proportion and activation degree of CD8+ T cells were increased. ### Conclusion: This study reveals that SFN, as a potential immunomodulator, can enhance the anti - tumor response of CD8+ T cells by eliminating MDSCs, providing a theoretical basis for the development of new tumor immunotherapy strategies.